Improving prediction of cardiovascular complications of cancer therapy: What does the future hold?

Future Cardiology

Volumn 11, Issue 4, 2015, Pages 383-387

  Barac, Ana ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Biomarkers; Cancer treatment; Cardiac imaging; Cardiotoxicity; Cardiovascular outcomes; Cardiovascular risk models; Targeted therapeutics

Indexed keywords

BIOLOGICAL MARKER;

CANCER RESEARCH; CANCER THERAPY; CARDIAC IMAGING; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL OBSERVATION; DISEASE ASSOCIATION; DISEASE MARKER; HEART INJURY; HUMAN; IMAGE ANALYSIS; NOTE; PRIORITY JOURNAL; CARDIOVASCULAR DISEASES; NEOPLASMS; RISK ASSESSMENT;

CARDIOTOXICITY; CARDIOVASCULAR DISEASES; HUMANS; NEOPLASMS; RISK ASSESSMENT;

EID: 84939446534     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/FCA.15.48     Document Type: Note

References (38)

1. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20(5), 1215-1221 (2002).
2. Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. N. Engl. J. Med. 367(22), 2150-2153 (2012).
3. Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin. Oncol. 28(1 Suppl. 3), 20-27 (2001).
4. Romond EH, Jeong JH, Rastogi P et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with nodepositive, human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30(31), 3792-3799 (2012).
5. Kumler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat. Rev. 40(2), 259-270 (2014).
6. Ewer MS, Von Hoff DD, Benjamin RS. A historical perspective of anthracycline cardiotoxicity. Heart Fail. Clin. 7(3), 363-372 (2011).
7. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J. Am. Coll. Cardiol. 64(9), 938-945 (2014).
8. Zhang S, Liu X, Bawa-Khalfe T et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18(11), 1639-1642 (2012).
9. Vejpongsa P, Yeh ET. Topoisomerase 2beta: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity. Clin Pharmacol Ther. 95(1), 45-52 (2014).
10. Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res. 113(6), 754-764 (2013).
11. Crone SA, Zhao YY, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8(5), 459-465 (2002).
12. Ky B, Kimmel SE, Safa RN et al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 120(4), 310-317 (2009).
13. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105(13), 1551-1554 (2002).
14. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370(9604), 2011-2019 (2007).
15. Moslehi J, Minamishima YA, Shi J et al. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation 122(10), 1004-1016 (2010).
16. Barac A. Yet another player in the cardiooncology conundrum?: deciphering the role of FLT3. J. Am. Coll. Cardiol. 63(10), 1020-1021 (2014).
17. Shelburne N, Adhikari B, Brell J et al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J. Natl Cancer Inst. 106(9), dju232 (2014).
18. Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109(22), 2749-2754 (2004).
19. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J. Clin. Oncol. 28(25), 3910-3916 (2010).
20. Lipshultz SE, Rifai N, Sallan SE et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96(8), 2641-2648 (1997).
21. Lipshultz SE, Miller TL, Scully RE et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J. Clin. Oncol. 30(10), 1042-1049 (2012).
22. Ky B, French B, Ruparel K et al. The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. J. Am. Coll. Cardiol. 58(4), 386-394 (2011).
23. Ky B, Putt M, Sawaya H et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J. Am. Coll. Cardiol. 63(8), 809-816 (2014).
24. Motiwala SR, Szymonifka J, Belcher A et al. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. J. Cardiovasc. Transl. Res. 7(2), 250-261 (2014).
25. Sawaya H, Sebag IA, Plana JC et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am. J. Cardiol. 107(9), 1375-1380 (2011).
26. Sawaya H, Sebag IA, Plana JC et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ. Cardiovasc. Imaging 5(5), 596-603 (2012).
27. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J. Am. Coll. Cardiol. 63(25 Pt A), 2751-2768 (2014).
28. Toro-Salazar OH, Gillan E, O'Loughlin MT et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ. Cardiovasc. Imaging 6(6), 873-880 (2013).
29. Jordan JH, D'Agostino RBJ, Hamilton CA et al. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using t1-weighted and t2-weighted cardiovascular magnetic resonance. Circ. Cardiovasc. Imaging 7(6), 872-879 (2014).
30. Lightfoot JC, D'Agostino RBJ, Hamilton CA et al. Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ. Cardiovasc. Imaging 3(5), 550-558 (2010).
31. Ling Y, Pong T, Vassiliou CC, Huang PL, Cima MJ. Implantable magnetic relaxation sensors measure cumulative exposure to cardiac biomarkers. Nat. Biotechnol. 29(3), 273-277 (2011).
32. Tham EB, Haykowsky MJ, Chow K et al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J. Cardiovasc. Magn. Reson. 15, 48 (2013).
33. Bowles EJ, Wellman R, Feigelson HS et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J. Natl Cancer Inst. 104(17), 1293-1305 (2012).
34. Darby SC, Ewertz M, McGale P et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368(11), 987-998 (2013).
35. Tsai HT, Isaacs C, Fu AZ et al. Risk of cardiovascular adverse events from trastuzumab (Herceptin) in elderly persons with breast cancer: a population-based study. Breast Cancer Res. Treat. 144(1), 163-170 (2014).
36. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J. Am. Heart Assoc. 3(1), e000472 (2014).
37. Strimbu K, Tavel JA. What are biomarkers? Curr. Opin. HIV AIDS. 5(6), 463-466 (2010).
38. Barac A, Murtagh G, Carver JR et al. Council Clinical Perspective: cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J. Am. Coll. Cardiol. 65(25), 2739-2746 (2015).